{"nctId":"NCT02692859","briefTitle":"A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine","startDateStruct":{"date":"2013-09"},"conditions":["Haemophilus Influenza"],"count":1992,"armGroups":[{"label":"Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)","type":"EXPERIMENTAL","interventionNames":["Biological: Hib conjugate vaccine"]},{"label":"Vaccine (Walvax Biotechnology Co., LTD.)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Hib conjugate vaccine"]}],"interventions":[{"name":"Hib conjugate vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy children aged 3-5 months/ 6-11 months/ 1-5 y for each age group\n* Without vaccination history of Hib conjugate vaccine\n* One of his/her guardians is able to understand and sign the informed consent\n* Subjects' guardian can and will comply with the requirements of the protocol\n* Subjects with temperature \\<=37.0°C on axillary setting\n\nExclusion Criteria:\n\n* Subject who has a medical or family history of any of the following: allergic history, seizure, epilepsy, brain or mental disease\n* Subject who is allergic to any ingredient of the vaccines\n* Subject with damaged or low immune function which has already been known\n* Subject who had a Hib disease medical history\n* Subject with acute febrile illness or infectious disease\n* Major congenital defects, developmental disorders or serious chronic illness\n* Thrombocytopenia, blood coagulation disorder or bleeding difficulties with intramuscular injection\n* Subject who has serious allergic history\n* Subject with other medical history not suitable for vaccination such as difficulty for blood collection\n* Any prior administration of immunodepressant or corticosteroids in last 6 months\n* Any prior administration of blood products in last 3 months\n* Any prior administration of other research medicine/vaccine in last 30 days\n* Any prior administration of any attenuated live vaccine in last 14 days\n* Any prior administration of subunit or inactivated vaccines in last 7 days, such as pneumococcal vaccine\n* Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or his/her guardian's signature on informed consent","healthyVolunteers":true,"sex":"ALL","minimumAge":"3 Months","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Solicited Adverse Reactions","description":"Number of Participants with Solicited Adverse Reactions","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"507","spread":null},{"groupId":"OG001","value":"480","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Vaccinees With Anti-polyribosylribitol Phosphate (PRP) Concentrations ≥1.0μg/ml","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of Unsolicited Adverse Reactions","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Event (SAE) During the Whole Study Period","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Proportion of Vaccinees With Anti-polyribosylribitol Phosphate (PRP) Concentrations ≥0.15μg/ml","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"the Anti-PRP Geometric Mean Concentrations (GMCs)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"the Anti-PRP Geometric Mean Fold Increase (GMFI)","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":996},"commonTop":[]}}}